M. Burke

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

David W. Johnson, G. Guyatt, M. Tonelli, 2021, BMJ.

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.

David W. Johnson, M. Tonelli, J. Craig, 2016, JAMA.

Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study.

David W. Johnson, C. Hawley, S. McDonald, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.

David W. Johnson, C. Hawley, G. Wong, 2016, Clinical journal of the American Society of Nephrology : CJASN.

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

M. Ruospo, S. Palmer, V. Saglimbene, 2022, BMJ.